Agenus grants 305,000 stock options to director

AGENUS INC director and officer Jennifer Buell received new stock option awards as part of her equity compensation.

Rhea-AI Filing Summary

AGENUS INC director and officer Jennifer Buell received new stock option awards as part of her equity compensation. On April 24, she was granted options to acquire 5,000 shares of common stock and a separate grant covering 300,000 shares, both with an exercise price of $3.90 per share and expiring on April 24, 2036.

The options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vest over three years. One-third of each award vests on April 24, 2027, with the remaining two-thirds vesting in equal quarterly installments thereafter. These are compensation-related grants rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 305,000 shares

Grant/Award 2 txns

Insider Buell Jennifer

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	300,000	$0.00	$0.00
Grant/Award	Stock Option	5,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 305,000 contracts (Direct)

Footnotes (1)

1. F1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027 and the balance vesting in equal quarterly installments thereafter.

Key Figures

Option grant size: 5,000 options Option grant size: 300,000 options Exercise price: $3.90 per share +3 more

6 metrics

Option grant size 5,000 options Award on April 24, 2026 for common stock

Option grant size 300,000 options Award on April 24, 2026 for common stock

Exercise price $3.90 per share Exercise price for both option grants

Expiration date April 24, 2036 Expiration for both stock option awards

Underlying shares total 305,000 shares Total common shares underlying both grants

Initial vesting date April 24, 2027 One-third of each award vests on this date

Key Terms

Stock Option, exercise price, 2019 Amended and Restated Equity Incentive Plan, vests over three years

4 terms

Stock Option financial

"security_title: Stock Option"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: 3.9000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2019 Amended and Restated Equity Incentive Plan financial

"Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan"

vests over three years financial

"and vests over three years with one-third of the award vesting"

FAQ

What did Jennifer Buell receive in this Agenus (AGEN) Form 4 filing?

Jennifer Buell received two stock option awards as equity compensation. The grants cover 5,000 and 300,000 shares of Agenus common stock, allowing future purchase at a fixed $3.90 exercise price, subject to vesting and an expiration date in 2036.

Are these Agenus (AGEN) transactions open-market buys or sells?

These transactions are stock option grants, not open-market buys or sells. The Form 4 shows compensation-related awards with a $3.90 exercise price, giving Buell the right to acquire shares in the future rather than reflecting immediate trading activity.

How do the Agenus (AGEN) stock options granted to Buell vest?

The options vest over three years. One-third of each award vests on April 24, 2027, and the remaining two-thirds vest in equal quarterly installments thereafter, as provided under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan.

What is the exercise price and expiration date of Buell’s Agenus (AGEN) options?

Both option grants have a $3.90 exercise price and expire on April 24, 2036. This means Buell can choose to exercise the options at $3.90 per share any time after vesting and before the expiration date, subject to plan terms.

How many Agenus (AGEN) shares can Buell acquire from these option grants?

The Form 4 reports options covering a total of 305,000 shares of Agenus common stock. One grant relates to 5,000 underlying shares, and the other to 300,000 underlying shares, all at a $3.90 exercise price, vesting over three years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buell Jennifer

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$3.9	04/24/2026		A		300,000		(1)	04/24/2036	Common Stock	300,000	$0	300,000	D
Stock Option	$3.9	04/24/2026		A		5,000		(1)	04/24/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027 and the balance vesting in equal quarterly installments thereafter.

Remarks:

Chairman of the Executive Counsel

	/s/Austin Charette, as Attorney-in-Fact for Jennifer Buell	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)